Business Context and Reporting Period
Company: Galectin Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 21, 2019
Event: Regulation FD Disclosure regarding the posting of a presentation on the Company's website detailing the results of its NASH-CX clinical trial (Exhibit 99.1).
Key Financial Metrics
This filing is a current report regarding a clinical trial update and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing discloses the release of new clinical data for the NASH-CX trial. No financial material changes versus prior periods are reported in this document.
Guidance, Outlook, and Risks
Management Commentary: The Company furnished the NASH-CX clinical trial results pursuant to Item 7.01 (Regulation FD Disclosure).
Legal Status of Information: The information in this report is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. It shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference.
Risks/Contingencies: No specific risks or contingencies are detailed in the body of this 8-K, other than the standard regulatory disclaimers regarding the status of the disclosed information.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached presentation) for specific details on the NASH-CX clinical trial results.
- Verify the Company's website for the full presentation referenced in the filing.
- Note that this 8-K does not contain audited financial data; refer to the most recent 10-K or 10-Q for financial metrics.
- Confirm the legal standing of the disclosed information as "furnished" rather than "filed" under the Exchange Act.